Denali Therapeutics
DNLI
203 hedge funds and large institutions have $2.88B invested in Denali Therapeutics in 2024 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 84 increasing their positions, 60 reducing their positions, and 34 closing their positions.
119% more call options, than puts
Call options by funds: $4.24M | Put options by funds: $1.93M
40% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 60
15% more capital invested
Capital invested by funds: $2.51B → $2.88B (+$365M)
1.08% less ownership
Funds ownership: 87.96% → 86.88% (-1.1%)
3% less funds holding
Funds holding: 210 → 203 (-7)
15% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 34
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$36.1M |
| 2 |
UBS AM
Chicago,
Illinois
|
+$30.9M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$29.8M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$20.7M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$20.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$36.3M |
| 2 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
-$28M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$24.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$19.2M |
| 5 |
Holocene Advisors
New York
|
-$15.4M |
DNLI Hedge Fund Activity: Q2 2024 in Review
203 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q2 2024, worth a combined $2.88B — up 15% from $2.51B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of DNLI and 29 opened new positions — a net loss of 5 holders — while 60 trimmed existing stakes and 84 added.
The largest buyer was AllianceBernstein, adding an estimated $36.1M. The largest seller was State Street, cutting an estimated $36.3M.
- 203 institutional investors held Denali Therapeutics (DNLI) as of Q2 2024, down from 210 in Q1 2024.
- Funds reported $2.88B of Denali Therapeutics stock for Q2 2024, up 15% quarter-over-quarter.
- 29 funds opened new Denali Therapeutics positions in Q2 2024 and 34 closed out, a net change of -5 holders.
- The largest Denali Therapeutics buyer in Q2 2024 was AllianceBernstein, an estimated $36.1M added.
- The largest Denali Therapeutics seller in Q2 2024 was State Street, an estimated $36.3M sold.
Based on aggregated 13F filings for Q2 2024.